StanleyKE. Prognostic factors for survival in patients with inoperable lung cancer.J Natl Cancer Inst.1980; 65(1): 25–32.
2.
BaldwinC, SpiroA, AhernR, EmeryPW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis.J Natl Cancer Inst.2012; 104(5): 371–85.
3.
DodsonS, BaracosVE, JatoiAMuscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies.Ann Rev Med.2011; 62(1): 265–79.
4.
EliaM, Van Bokhorst-de van der SchuerenMAE, GarveyJEnteral (oral or tube administration) nutritional support and eicosa-pentaenoic acid in patients with cancer: a systematic review.Int J Oncol.2006; 28(1): 5–23.
5.
ChampCE, VolekJS, SiglinJ, JinL, SimoneNL. Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data?Int J Breast Cancer.2012; 2012: 506868.
6.
ShuklaSK, GebregiworgisT, PurohitVMetabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia.Cancer Metab.2014; 2(1): 18.
7.
FearonK, StrasserF, AnkerSDDefinition and classification of cancer cachexia: an international consensus.Lancet Oncol.2011; 12(5): 489–95.
8.
SuzukiH, AsakawaA, AmitaniH, NakamuraN, InuiA. Cancer cachexia—pathophysiology and management.J Gastroenterol.2013; 48(5): 574–94.
9.
VaughanVC, MartinP, LewandowskiPA. Cancer cachexia: impact, mechanisms and emerging treatments.J Cachexia Sarcopenia Muscle.2013; 4(2): 95–109.
10.
FearonKC, BarberMD, FalconerJSPancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia.World J Surg.1999; 23(6): 584–8.
11.
ChevalierS, FarsijaniS. Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment.Appl Physiol Nutr Metab.2014; 39(6): 643–53.
12.
BarberMD. The pathophysiology and treatment of cancer cachexia.Nutr Clin Pract.2002; 17(4): 203–9.
13.
KimEH, LeeH, ChungHImpact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer.Clin Res Hepatol Gastroenterol.2014; 38(3): 372–8.
14.
YangY, MauldinPD, EbelingMEffect of metabolic syndrome and its components on recurrence and survival in colon cancer patients.Cancer.2013; 119(8): 1512–20.
15.
XiangY, XiongH, CuiZThe association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence.J Exp Clin Cancer Res.2013Feb 13; 32: 9.
16.
CoweyS, HardyRW. The metabolic syndrome: A high-risk state for cancer?Am J Pathol.2006; 169(5): 1505–22.
17.
KlementRJ, ChampCE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation.Cancer Metastasis Rev.2014 Jan 17 [Epub ahead of print].
18.
SattlerUGA, Mueller-KlieserW. The anti-oxidant capacity of tumour glycolysis.Int J Radiat Biol.2009; 85(11): 963–71.
SethiG, ShanmugamMK, RamachandranL, KumarAP, TergaonkarV. Multifaceted link between cancer and inflammation.Biosci Rep.2012; 32(1): 1–15.
21.
HanahanD, WeinbergRA. Hallmarks of cancer: the next generation.Cell.2011; 144(5): 646–74.
22.
SuezJ, KoremT, ZeeviDArtificial sweeteners induce glucose intolerance by altering the gut microbiota.Nature.2014; 514(7521): 181–6.
23.
BindelsLB, DelzenneNM. Muscle wasting: the gut microbiota as a new therapeutic target?Int J Biochem Cell Biol.2013; 45(10): 2186–90.
24.
KleinGL, PetschowBW, ShawAL, WeaverE. Gut barrier dysfunction and microbial translocation in cancer cachexia.Curr Opin Support Palliat Care.2013 Dec; 7(4): 361–7.
25.
TortiSV, TortiFM. Iron and cancer: more ore to be mined.Nat Rev Cancer.2013; 13(5): 342–55.
26.
WeinbergED. The hazards of iron loading.Metallomics.2010; 2(11): 732–40.
27.
KentS, WeinbergED, Stuart-MacadamP. Dietary and prophylactic iron supplements: Helpful or harmful?Hum Nat.1990; 1(1): 53–79.
28.
BrewerGJ. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.J Trace Elem Med Biol.2014 Aug 10. pii: S0946-672X(14)00146-1.
29.
GupteA, MumperRJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment.Cancer Treat Rev.2009 Feb; 35(1): 32–46.
30.
EbbingM, B⊘naaKH, Nyg°rdOCancer incidence and mortality after treatment with folic acid and vitamin B12.JAMA.2009; 302(19): 2119–26.
KimY-I. Will mandatory folic acid fortification prevent or promote cancer?Am. J. Clin. Nutr.2004; 80(5): 1123–8.
33.
SeyfriedTN, FloresRE, PoffAM, D'AgostinoDP. Cancer as a metabolic disease: implications for novel therapeutics.Carcinogenesis.2014; 35(3): 515–27.
34.
PhinneySD, BistrianBR, WolfeRR, BlackburnGL. The human metabolic response to chronic ketosis without caloric restriction: physical and biochemical adaptation.Metab Clin Exp.1983; 32(8): 757–68.
35.
TisdaleMJ, BrennanRA, FearonKC. Reduction of weight loss and tumour size in a cachexia model by a high fat diet.Br J Cancer.1987; 56(1): 39–43.
36.
SilvérioR, LavianoA, Rossi FanelliF, SeelaenderM. l-carnitine and cancer cachexia: Clinical and experimental aspects.J Cachexia Sarcopenia Muscle.2011; 2(1): 37–44.
37.
GramignanoG, LussoMR, MadedduCEfficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.Nutrition.2006; 22(2): 136–45.
38.
Di GirolamoFG, SitulinR, MazzuccoSOmega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia.Curr Opin Clin Nutr Metab Care.2014; 17(2): 145–50.
39.
MurphyRA, YeungE, MazurakVC, MourtzakisM. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia.Br J Cancer.2011; 105(10): 1469–73.
40.
WigmoreSJ, BarberMD, RossJA, TisdaleMJ, FearonKC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer.Nutr Cancer.2000; 36(2): 177–84.
41.
MantovaniG, MaccioA, MadedduCRandomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.Oncologist.2010; 15(2): 200–11.
42.
MacciòA, MadedduC, GramignanoGA randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.Gynecol Oncol.2012; 124(3): 417–25.
43.
StojcevZ, MatysiakK, DuszewskiM, BanasiewiczT. The role of dietary nutrition in stomach cancer.Contemp Oncol.2013; 17(4): 343–5.
44.
KapalaA, LangeE. Possibility of pain reduction by dietary intervention in patients with advanced cancer.Ann Agric Environ Med.2013; 1: 18–22.
LeserM, LedesmaN, BergersonS, TrujilloE. Oncology Nutrition for Clinical Practice.Chicago, IL: Oncology Nutrition Dietetic Practice Group; 2013: 115.
47.
NicoliniA, FerrariP, MasoniMCMalnutrition, anorexia and cachexia in cancer patients: a mini-review on pathogenesis and treatmentBiomed Pharmacol.2013; 67(8):807–17.
48.
RyanJL. Treatment of chemotherapy-induced nausea in cancer patients.Eur Oncol.2010; 6(2): 14–6.
49.
PattersonWL, GeorgelPT. Breaking the cycle: the role of omega-3 polyunsaturated fatty acids in inflammatory-driven cancers.Biochem Cell Biol.2014; 8: 1–8.
50.
WatanabeT, ShibataM, NishiyamaHSerum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer.Oncol Lett.2014; 7(2): 373–7.
51.
InuiA. Cancer anorexia-cachexia syndrome: current issues in research and management.Am Cancer Soc.2002; 52(2)72–91.
52.
MaggioM, DeVitaF, LauretaniFIGF-1, the cross road of the nutritional, inflammatory and hormonal pathways to frailty.Nutrients.2013; 5(10): 4184–205.
53.
KienleGS, AlbonicoHU, BaarsE, HamreHJ, ZimmermannP, KieneH. Anthroposophic medicine: an integrative medical system originating in Europe.Global Adv Health Med.2013,2(6):20–31.
54.
HeusserP, BraunSB, ZieglerRPalliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine.Forsch Komplementmed.2006; 13(2): 94–100.
55.
HeusserP, BraunSB, BertschyMPalliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits.Forsch Komplementmed2006; 13(3): 156–66.
56.
HeusserP, KienleG. Anthroposophic medicine, integrative oncology, and mistletoe therapy of cancer. In: Integrative oncology.Second ed.AbramsD, WeilA, editors. New York: Oxford University Press; 2014: 560–88.